^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    ceralasertib (AZD6738) (ATR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JCO Precis Oncol
    Title:

    Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)

    Published date:
    09/07/2021
    Excerpt:
    Overall response rate was 8.3% and CBR was 62.5% among the entire cohort. Two of five patients with tumor harboring ATM mutation achieved CR or SD ongoing at 24+ months, respectively (CBR 40%). Of seven patients with PARP inhibitor-resistant HGSOC, one achieved PR (-90%) and five had SD ranging 16-72 weeks (CBR 86%). Olaparib with ceralasertib demonstrated preliminary activity in ATM-mutated tumors and in PARP inhibitor-resistant BRCA1/2-mutated HGSOC.
    DOI:
    10.1200/PO.20.00439